Skip to main content

Table 2 Comparison of CSF analysis and LCT measurements between AD and healthy groups

From: Increased CSF tau level is correlated with decreased lamina cribrosa thickness

 

AD group (n = 18)

Healthy group (n = 26)

P value

CSF analysis

 CSF pressure (mmHg)a

12.8 ± 2.6

14.4 ± 2.5

0.062

 Aβ1–42 (pg/ml)a

306.52 ± 116.21

463.46 ± 124.69

<0.001

 T-tau (pg/ml)b

110.04 ± 57.08

62.51 ± 19.73

<0.001

 P-tau181P (pg/ml)b

51.66 ± 19.40

28.07 ± 14.14

<0.001

LCT measurements

 Superior LCT (μm)a

227.61 ± 42.07

238.81 ± 42.08

0.390

 Central LCT (μm)a

267.72 ± 31.35

262.65 ± 49.05

0.701

 Inferior LCT (μm)b

232.00 ± 45.67

242.27 ± 46.60

0.423

 Average LCT (μm)a

242.46 ± 31.93

247.95 ± 37.55

0.616

  1. Data are presented as the mean ± standard deviation, unless otherwise specified. Statistically significant values are shown in bold
  2. aComparisons were made using an independent-samples t test
  3. bComparisons were made using a Mann–Whitney U test
  4. 1–42 amyloid β1–42, AD Alzheimer’s disease, CSF cerebrospinal fluid, LCT lamina cribrosa thickness, P-tau 181P , phosphorylated tau181P, T-tau total tau